Vodobatinib
| CAS号 | 1388803-90-4 | 货号 | BCP43522 |
| 中文名 | Vodobatinib | ||
| 英文名 | Vodobatinib | ||
| 中文别名 | |||
| 英文别名 | K-0706; K0706; K0706; | ||
| 分子式 | C27H20ClN3O2 | 分子量 | 453.92 |
| 生物活性 | Vodobatinib is an orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, vodobatinib selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the 'gatekeeper' resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis. | ||
| 信号通路 | Angiogenesis/Protein Tyrosine Kinase | ||
| 靶 点 | Src/Bcr Abl | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！